Report cover image

Global Montelukast API Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 194 Pages
SKU # APRC20360189

Description

Summary

According to APO Research, the global Montelukast API market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Montelukast API is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Montelukast API is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Montelukast API market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Montelukast API is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Montelukast API market include Merck, Mylan, Teva Pharmaceutical Industries, Sun Pharma, Sanyo Chemical Industries, Morepen Laboratories, Intas Pharmaceuticals, Delmar Chemicals and Cipla, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Montelukast API, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Montelukast API, also provides the sales of main regions and countries. Of the upcoming market potential for Montelukast API, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Montelukast API sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Montelukast API market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Montelukast API sales, projected growth trends, production technology, application and end-user industry.

Montelukast API Segment by Company

Merck
Mylan
Teva Pharmaceutical Industries
Sun Pharma
Sanyo Chemical Industries
Morepen Laboratories
Intas Pharmaceuticals
Delmar Chemicals
Cipla
Apotex
Montelukast API Segment by Type

Chewable Tablet
Oral Solution
Tablet
Montelukast API Segment by Application

Bronchospasm
Urticaria
Asthma
Allergic Rhinitis
Others
Montelukast API Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Montelukast API status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Montelukast API market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Montelukast API significant trends, drivers, influence factors in global and regions.
6. To analyze Montelukast API competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Montelukast API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Montelukast API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Montelukast API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Montelukast API market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Montelukast API industry.
Chapter 3: Detailed analysis of Montelukast API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Montelukast API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Montelukast API in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Table of Contents

194 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Montelukast API Sales Value (2020-2031)
1.2.2 Global Montelukast API Sales Volume (2020-2031)
1.2.3 Global Montelukast API Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Montelukast API Market Dynamics
2.1 Montelukast API Industry Trends
2.2 Montelukast API Industry Drivers
2.3 Montelukast API Industry Opportunities and Challenges
2.4 Montelukast API Industry Restraints
3 Montelukast API Market by Company
3.1 Global Montelukast API Company Revenue Ranking in 2024
3.2 Global Montelukast API Revenue by Company (2020-2025)
3.3 Global Montelukast API Sales Volume by Company (2020-2025)
3.4 Global Montelukast API Average Price by Company (2020-2025)
3.5 Global Montelukast API Company Ranking (2023-2025)
3.6 Global Montelukast API Company Manufacturing Base and Headquarters
3.7 Global Montelukast API Company Product Type and Application
3.8 Global Montelukast API Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Montelukast API Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Montelukast API Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Montelukast API Market by Type
4.1 Montelukast API Type Introduction
4.1.1 Chewable Tablet
4.1.2 Oral Solution
4.1.3 Tablet
4.2 Global Montelukast API Sales Volume by Type
4.2.1 Global Montelukast API Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Montelukast API Sales Volume by Type (2020-2031)
4.2.3 Global Montelukast API Sales Volume Share by Type (2020-2031)
4.3 Global Montelukast API Sales Value by Type
4.3.1 Global Montelukast API Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Montelukast API Sales Value by Type (2020-2031)
4.3.3 Global Montelukast API Sales Value Share by Type (2020-2031)
5 Montelukast API Market by Application
5.1 Montelukast API Application Introduction
5.1.1 Bronchospasm
5.1.2 Urticaria
5.1.3 Asthma
5.1.4 Allergic Rhinitis
5.1.5 Others
5.2 Global Montelukast API Sales Volume by Application
5.2.1 Global Montelukast API Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Montelukast API Sales Volume by Application (2020-2031)
5.2.3 Global Montelukast API Sales Volume Share by Application (2020-2031)
5.3 Global Montelukast API Sales Value by Application
5.3.1 Global Montelukast API Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Montelukast API Sales Value by Application (2020-2031)
5.3.3 Global Montelukast API Sales Value Share by Application (2020-2031)
6 Montelukast API Regional Sales and Value Analysis
6.1 Global Montelukast API Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Montelukast API Sales by Region (2020-2031)
6.2.1 Global Montelukast API Sales by Region: 2020-2025
6.2.2 Global Montelukast API Sales by Region (2026-2031)
6.3 Global Montelukast API Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Montelukast API Sales Value by Region (2020-2031)
6.4.1 Global Montelukast API Sales Value by Region: 2020-2025
6.4.2 Global Montelukast API Sales Value by Region (2026-2031)
6.5 Global Montelukast API Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Montelukast API Sales Value (2020-2031)
6.6.2 North America Montelukast API Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Montelukast API Sales Value (2020-2031)
6.7.2 Europe Montelukast API Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Montelukast API Sales Value (2020-2031)
6.8.2 Asia-Pacific Montelukast API Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Montelukast API Sales Value (2020-2031)
6.9.2 South America Montelukast API Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Montelukast API Sales Value (2020-2031)
6.10.2 Middle East & Africa Montelukast API Sales Value Share by Country, 2024 VS 2031
7 Montelukast API Country-level Sales and Value Analysis
7.1 Global Montelukast API Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Montelukast API Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Montelukast API Sales by Country (2020-2031)
7.3.1 Global Montelukast API Sales by Country (2020-2025)
7.3.2 Global Montelukast API Sales by Country (2026-2031)
7.4 Global Montelukast API Sales Value by Country (2020-2031)
7.4.1 Global Montelukast API Sales Value by Country (2020-2025)
7.4.2 Global Montelukast API Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Montelukast API Sales Value Growth Rate (2020-2031)
7.5.2 USA Montelukast API Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Montelukast API Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Montelukast API Sales Value Growth Rate (2020-2031)
7.6.2 Canada Montelukast API Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Montelukast API Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Montelukast API Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Montelukast API Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Montelukast API Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Montelukast API Sales Value Growth Rate (2020-2031)
7.8.2 Germany Montelukast API Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Montelukast API Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Montelukast API Sales Value Growth Rate (2020-2031)
7.9.2 France Montelukast API Sales Value Share by Type, 2024 VS 2031
7.9.3 France Montelukast API Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Montelukast API Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Montelukast API Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Montelukast API Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Montelukast API Sales Value Growth Rate (2020-2031)
7.11.2 Italy Montelukast API Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Montelukast API Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Montelukast API Sales Value Growth Rate (2020-2031)
7.12.2 Spain Montelukast API Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Montelukast API Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Montelukast API Sales Value Growth Rate (2020-2031)
7.13.2 Russia Montelukast API Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Montelukast API Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Montelukast API Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Montelukast API Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Montelukast API Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Montelukast API Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Montelukast API Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Montelukast API Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Montelukast API Sales Value Growth Rate (2020-2031)
7.16.2 China Montelukast API Sales Value Share by Type, 2024 VS 2031
7.16.3 China Montelukast API Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Montelukast API Sales Value Growth Rate (2020-2031)
7.17.2 Japan Montelukast API Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Montelukast API Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Montelukast API Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Montelukast API Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Montelukast API Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Montelukast API Sales Value Growth Rate (2020-2031)
7.19.2 India Montelukast API Sales Value Share by Type, 2024 VS 2031
7.19.3 India Montelukast API Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Montelukast API Sales Value Growth Rate (2020-2031)
7.20.2 Australia Montelukast API Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Montelukast API Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Montelukast API Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Montelukast API Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Montelukast API Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Montelukast API Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Montelukast API Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Montelukast API Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Montelukast API Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Montelukast API Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Montelukast API Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Montelukast API Sales Value Growth Rate (2020-2031)
7.24.2 Chile Montelukast API Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Montelukast API Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Montelukast API Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Montelukast API Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Montelukast API Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Montelukast API Sales Value Growth Rate (2020-2031)
7.26.2 Peru Montelukast API Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Montelukast API Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Montelukast API Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Montelukast API Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Montelukast API Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Montelukast API Sales Value Growth Rate (2020-2031)
7.28.2 Israel Montelukast API Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Montelukast API Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Montelukast API Sales Value Growth Rate (2020-2031)
7.29.2 UAE Montelukast API Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Montelukast API Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Montelukast API Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Montelukast API Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Montelukast API Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Montelukast API Sales Value Growth Rate (2020-2031)
7.31.2 Iran Montelukast API Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Montelukast API Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Montelukast API Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Montelukast API Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Montelukast API Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Merck
8.1.1 Merck Comapny Information
8.1.2 Merck Business Overview
8.1.3 Merck Montelukast API Sales, Value and Gross Margin (2020-2025)
8.1.4 Merck Montelukast API Product Portfolio
8.1.5 Merck Recent Developments
8.2 Mylan
8.2.1 Mylan Comapny Information
8.2.2 Mylan Business Overview
8.2.3 Mylan Montelukast API Sales, Value and Gross Margin (2020-2025)
8.2.4 Mylan Montelukast API Product Portfolio
8.2.5 Mylan Recent Developments
8.3 Teva Pharmaceutical Industries
8.3.1 Teva Pharmaceutical Industries Comapny Information
8.3.2 Teva Pharmaceutical Industries Business Overview
8.3.3 Teva Pharmaceutical Industries Montelukast API Sales, Value and Gross Margin (2020-2025)
8.3.4 Teva Pharmaceutical Industries Montelukast API Product Portfolio
8.3.5 Teva Pharmaceutical Industries Recent Developments
8.4 Sun Pharma
8.4.1 Sun Pharma Comapny Information
8.4.2 Sun Pharma Business Overview
8.4.3 Sun Pharma Montelukast API Sales, Value and Gross Margin (2020-2025)
8.4.4 Sun Pharma Montelukast API Product Portfolio
8.4.5 Sun Pharma Recent Developments
8.5 Sanyo Chemical Industries
8.5.1 Sanyo Chemical Industries Comapny Information
8.5.2 Sanyo Chemical Industries Business Overview
8.5.3 Sanyo Chemical Industries Montelukast API Sales, Value and Gross Margin (2020-2025)
8.5.4 Sanyo Chemical Industries Montelukast API Product Portfolio
8.5.5 Sanyo Chemical Industries Recent Developments
8.6 Morepen Laboratories
8.6.1 Morepen Laboratories Comapny Information
8.6.2 Morepen Laboratories Business Overview
8.6.3 Morepen Laboratories Montelukast API Sales, Value and Gross Margin (2020-2025)
8.6.4 Morepen Laboratories Montelukast API Product Portfolio
8.6.5 Morepen Laboratories Recent Developments
8.7 Intas Pharmaceuticals
8.7.1 Intas Pharmaceuticals Comapny Information
8.7.2 Intas Pharmaceuticals Business Overview
8.7.3 Intas Pharmaceuticals Montelukast API Sales, Value and Gross Margin (2020-2025)
8.7.4 Intas Pharmaceuticals Montelukast API Product Portfolio
8.7.5 Intas Pharmaceuticals Recent Developments
8.8 Delmar Chemicals
8.8.1 Delmar Chemicals Comapny Information
8.8.2 Delmar Chemicals Business Overview
8.8.3 Delmar Chemicals Montelukast API Sales, Value and Gross Margin (2020-2025)
8.8.4 Delmar Chemicals Montelukast API Product Portfolio
8.8.5 Delmar Chemicals Recent Developments
8.9 Cipla
8.9.1 Cipla Comapny Information
8.9.2 Cipla Business Overview
8.9.3 Cipla Montelukast API Sales, Value and Gross Margin (2020-2025)
8.9.4 Cipla Montelukast API Product Portfolio
8.9.5 Cipla Recent Developments
8.10 Apotex
8.10.1 Apotex Comapny Information
8.10.2 Apotex Business Overview
8.10.3 Apotex Montelukast API Sales, Value and Gross Margin (2020-2025)
8.10.4 Apotex Montelukast API Product Portfolio
8.10.5 Apotex Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Montelukast API Value Chain Analysis
9.1.1 Montelukast API Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Montelukast API Sales Mode & Process
9.2 Montelukast API Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Montelukast API Distributors
9.2.3 Montelukast API Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.